Cargando…

Assessment of malignancy and PSMA expression of uncertain bone foci in [(18)F]PSMA-1007 PET/CT for prostate cancer—a single-centre experience of PET-guided biopsies

PURPOSE: Uncertain focal bone uptake (UBU) with intensive radiopharmaceutical avidity are frequently observed in patients undergoing [(18)F]PSMA-1007 PET/CT for the detection of prostate cancer (PC). Such foci can pose diagnostic conundrums and risk incorrect staging. The aim of this short communica...

Descripción completa

Detalles Bibliográficos
Autores principales: Vollnberg, Bernd, Alberts, Ian, Genitsch, Vera, Rominger, Axel, Afshar-Oromieh, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399054/
https://www.ncbi.nlm.nih.gov/pubmed/35482114
http://dx.doi.org/10.1007/s00259-022-05745-5
_version_ 1784772437543485440
author Vollnberg, Bernd
Alberts, Ian
Genitsch, Vera
Rominger, Axel
Afshar-Oromieh, Ali
author_facet Vollnberg, Bernd
Alberts, Ian
Genitsch, Vera
Rominger, Axel
Afshar-Oromieh, Ali
author_sort Vollnberg, Bernd
collection PubMed
description PURPOSE: Uncertain focal bone uptake (UBU) with intensive radiopharmaceutical avidity are frequently observed in patients undergoing [(18)F]PSMA-1007 PET/CT for the detection of prostate cancer (PC). Such foci can pose diagnostic conundrums and risk incorrect staging. The aim of this short communication is to share the results of PET-guided biopsies of such foci. METHODS: A retrospective analysis revealed 10 patients who were referred to our department for PET-guided biopsy of UBU visible in a previous [(18)F]PSMA-1007 PET/CT. [(18)F]-PSMA-1007 PET-guided biopsy was conducted for 11 PSMA-avid bone foci in these 10 patients. The biopsy materials were analysed for tissue typing, and immunohistochemistry (IHC) was performed for prostate-specific-membrane-antigen (PSMA) expression. The scans were analysed by two experienced physicians in a consensus read for clinical characteristics and radiopharmaceutical uptake of foci. RESULTS: One out of 11 (9.1%) of the foci biopsied was confirmed as bone metastasis of PC with intense PSMA-expression, while 10/11 (90.9%) foci were revealed to be unremarkable bone tissue without evidence of PSMA expression at IHC. Amongst all bone foci assessed by biopsy, eight were visually classified as being at high risk of malignancy in the PET/CT (SUVmean 12.0 ± 8.1; SUVmax 18.8 ± 13.1), three as equivocal (SUVmean 4.6 ± 2.1; SUVmax 7.2 ± 3.0) and zero as low risk. No UBU had any CT correlate. CONCLUSIONS: This cohort biopsy revealed that a small but relevant number of UBU are true metastases. For those confirmed as benign, no PSMA expression at IHC was observed, suggesting a non-PSMA mediated cause for intensive [(18)F]PSMA-1007 uptake of which the reason remains unclear. Readers must interpret such foci with caution in order to reduce the risk of erroneous staging and subsequent treatment. PET-guided biopsy, particularly in the absence of morphological changes in the CT, can be a useful method to clarify such foci. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-022-05745-5.
format Online
Article
Text
id pubmed-9399054
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-93990542022-08-25 Assessment of malignancy and PSMA expression of uncertain bone foci in [(18)F]PSMA-1007 PET/CT for prostate cancer—a single-centre experience of PET-guided biopsies Vollnberg, Bernd Alberts, Ian Genitsch, Vera Rominger, Axel Afshar-Oromieh, Ali Eur J Nucl Med Mol Imaging Short Communication PURPOSE: Uncertain focal bone uptake (UBU) with intensive radiopharmaceutical avidity are frequently observed in patients undergoing [(18)F]PSMA-1007 PET/CT for the detection of prostate cancer (PC). Such foci can pose diagnostic conundrums and risk incorrect staging. The aim of this short communication is to share the results of PET-guided biopsies of such foci. METHODS: A retrospective analysis revealed 10 patients who were referred to our department for PET-guided biopsy of UBU visible in a previous [(18)F]PSMA-1007 PET/CT. [(18)F]-PSMA-1007 PET-guided biopsy was conducted for 11 PSMA-avid bone foci in these 10 patients. The biopsy materials were analysed for tissue typing, and immunohistochemistry (IHC) was performed for prostate-specific-membrane-antigen (PSMA) expression. The scans were analysed by two experienced physicians in a consensus read for clinical characteristics and radiopharmaceutical uptake of foci. RESULTS: One out of 11 (9.1%) of the foci biopsied was confirmed as bone metastasis of PC with intense PSMA-expression, while 10/11 (90.9%) foci were revealed to be unremarkable bone tissue without evidence of PSMA expression at IHC. Amongst all bone foci assessed by biopsy, eight were visually classified as being at high risk of malignancy in the PET/CT (SUVmean 12.0 ± 8.1; SUVmax 18.8 ± 13.1), three as equivocal (SUVmean 4.6 ± 2.1; SUVmax 7.2 ± 3.0) and zero as low risk. No UBU had any CT correlate. CONCLUSIONS: This cohort biopsy revealed that a small but relevant number of UBU are true metastases. For those confirmed as benign, no PSMA expression at IHC was observed, suggesting a non-PSMA mediated cause for intensive [(18)F]PSMA-1007 uptake of which the reason remains unclear. Readers must interpret such foci with caution in order to reduce the risk of erroneous staging and subsequent treatment. PET-guided biopsy, particularly in the absence of morphological changes in the CT, can be a useful method to clarify such foci. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-022-05745-5. Springer Berlin Heidelberg 2022-04-28 2022 /pmc/articles/PMC9399054/ /pubmed/35482114 http://dx.doi.org/10.1007/s00259-022-05745-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Short Communication
Vollnberg, Bernd
Alberts, Ian
Genitsch, Vera
Rominger, Axel
Afshar-Oromieh, Ali
Assessment of malignancy and PSMA expression of uncertain bone foci in [(18)F]PSMA-1007 PET/CT for prostate cancer—a single-centre experience of PET-guided biopsies
title Assessment of malignancy and PSMA expression of uncertain bone foci in [(18)F]PSMA-1007 PET/CT for prostate cancer—a single-centre experience of PET-guided biopsies
title_full Assessment of malignancy and PSMA expression of uncertain bone foci in [(18)F]PSMA-1007 PET/CT for prostate cancer—a single-centre experience of PET-guided biopsies
title_fullStr Assessment of malignancy and PSMA expression of uncertain bone foci in [(18)F]PSMA-1007 PET/CT for prostate cancer—a single-centre experience of PET-guided biopsies
title_full_unstemmed Assessment of malignancy and PSMA expression of uncertain bone foci in [(18)F]PSMA-1007 PET/CT for prostate cancer—a single-centre experience of PET-guided biopsies
title_short Assessment of malignancy and PSMA expression of uncertain bone foci in [(18)F]PSMA-1007 PET/CT for prostate cancer—a single-centre experience of PET-guided biopsies
title_sort assessment of malignancy and psma expression of uncertain bone foci in [(18)f]psma-1007 pet/ct for prostate cancer—a single-centre experience of pet-guided biopsies
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399054/
https://www.ncbi.nlm.nih.gov/pubmed/35482114
http://dx.doi.org/10.1007/s00259-022-05745-5
work_keys_str_mv AT vollnbergbernd assessmentofmalignancyandpsmaexpressionofuncertainbonefociin18fpsma1007petctforprostatecancerasinglecentreexperienceofpetguidedbiopsies
AT albertsian assessmentofmalignancyandpsmaexpressionofuncertainbonefociin18fpsma1007petctforprostatecancerasinglecentreexperienceofpetguidedbiopsies
AT genitschvera assessmentofmalignancyandpsmaexpressionofuncertainbonefociin18fpsma1007petctforprostatecancerasinglecentreexperienceofpetguidedbiopsies
AT romingeraxel assessmentofmalignancyandpsmaexpressionofuncertainbonefociin18fpsma1007petctforprostatecancerasinglecentreexperienceofpetguidedbiopsies
AT afsharoromiehali assessmentofmalignancyandpsmaexpressionofuncertainbonefociin18fpsma1007petctforprostatecancerasinglecentreexperienceofpetguidedbiopsies